Among the entire cohort of patients with MM refractory to an anti-CD38 mAb and treated with subsequent SoC therapy (n = 346), the median PFS from start of subsequent therapy was 4.6 (95% CI 4.1–5.6) months, and the median OS was 13.3 (95% CI 10.6–16.6) months (Fig. 3). This evidence concerns the gene CD38 and Miyoshi myopathy.